Company: APXT
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001213900-25-097069
Chunk: 7

Company: Apex Treasury Corp
Filing Date: 2025-10-07
Form: S-1/A
Chunk 7
---
 time of our initial business combination as a result of the anti -dilution provisions contained therein. Any such issuances would dilute the interest of our shareholders and likely present other risks” on page66, “ Dilution” on page 104 and “ Proposed Business — Our Sponsor” on page 123 for more information. In addition, our sponsor and the underwriters have committed to purchase an aggregate of 7,000,000 warrants (or 7,750,000 warrants if the underwriters’ over -allotmentoption is exercised in full), each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or $7,000,000 (or $7,750,000 if the underwriters’ overallotment option is exercised in full), in a private placement that will close simultaneously with the closing of this offering, which we refer to collectively as the “private placement warrants.” Of those 7,000,000 private placement warrants (or 7,750,000 private placement warrants if the underwriters’ overallotment option is exercised in full), our sponsor has agreed to purchase 4,500,000 (or 4,875,000 private placement warrants if the underwriters’ overallotment option is exercised in full) private placement warrants and the underwriters have agreed to purchase 2,500,000 private placement warrants (or 2,875,000 private placement warrants if the underwriters’ overallotment option is exercised in full). Each whole private placement warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment, terms and limitations as described herein. The private placement warrants will become exercisable 30 days after the completion of our initial business combination, as described in this prospectus. The private placement warrants are identical to the public warrants sold in this offering, subject to certain limited exceptions as described in this prospectus. Our public shareholders may also experience material dilution from the exercise of such private placement warrants, which private placement warrants may be exercised on a cashless basis under the circumstances specified in the warrant agreement filed as an exhibit to the registration statement of which this prospectus forms a part. Certain accredited investors (which may include certain of our directors, non -managementofficers and advisors), which we refer to as the “non -managingsponsor investors” throughout this prospectus, have expressed an interest to purchase, indirectly through